Kraig Jacobson
Allergy & Immunology · Eugene, ORNPI 1255323515
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Biocryst Pharmaceuticals, Inc. at 30.6% of the total. Reporting peaked in 2020 at $3,935 and has fallen 99.6% since, to $17 in 2025.
Across 177 payments — averaging $41.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$2K
- AstraZeneca$1K
- Optinose US, Inc.$811
- GSK$732
- Takeda Pharmaceuticals U.S.A., Inc.$428
- Regeneron Healthcare Solutions, Inc.$419
- plus $1K from 17 others
Across 41 payments — averaging $4679.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$97K
- Cipla USA Inc.$91K
- Novartis$5K
What the payments were for
- Consulting fees$3,12943%
- Food & beverage$4,05755%
- Education$1592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 1 | $2,250 |
| AstraZeneca | 35 | $1,221 |
| Optinose US, Inc. | 3 | $811 |
| GSK | 44 | $732 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $428 |
| Regeneron Healthcare Solutions, Inc. | 10 | $419 |
| CSL Behring | 16 | $323 |
| Genentech USA, Inc. | 4 | $165 |
| Shire North American Group Inc | 6 | $158 |
| Biocryst US Sales Co., LLC | 4 | $158 |
| Octapharma USA, Inc. | 5 | $116 |
| Sanofi | 4 | $91 |
| Boehringer Ingelheim | 4 | $79 |
| ADMA Biomanufacturing LLC | 3 | $79 |
| Pfizer | 4 | $73 |
| Novartis | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Pharming Healthcare, Inc. | 2 | $35 |
| Alk-abello, Inc | 1 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Amgen | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,345 in reported general payments places this provider in the 75th percentile of 33 allergy & immunology providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $91,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,068 |
| Arnuity ElliptaFluticasone Furoate | 24 | $7,011 |
| Cromolyn Sodium | 20 | $6,667 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $5,072 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $3,221 |
| Montelukast Sodium | 136 | $2,629 |
| Fluticasone Propionate | 26 | $933 |
| Ipratropium Bromide | 12 | $803 |
| Azelastine Hcl | 26 | $670 |
| Pantoprazole Sodium | 23 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $323 | $91,57126 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $732 | $30,07955 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Eugene
- Maxwell LiEugene$5K
- Sarah KehlEugene$3K
- Jason FriesenEugene$2K
- Richard BuckEugene$501
- Adam WilliamsBend$138K
- Shyam JoshiPortland$116K
- Stephen FritzHappy Valley$42K
- Anthony MontanaroPortland$25K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.